J.Molner
Company Announcement

J.Molner submits second drug to Health Canada

Tallinn, 2023-03-28 08:31 CEST -- J. Molner has successfully presented its second submission to Health Canada. Molner’s generic injectable antiemetic drug, MOC-002, is expected to be approved in Q2-Q3, 2024.

         For additional information please contact:
         
         Jason Grenfell-Gardner
         J.Molner AS
         Management Board member
         +372 536 00 346
         jason@jmolner.com